l carnitine tmao nature medicine 2013 koeth γ–Butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of L-carnitine to L-Carnitine intake and high trimethylamine

L Carnitine intake and high trimethylamine N oxide plasma levels correlate with low aortic lesions in ApoE transgenic mice expressing CETP ScienceDirect Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L Carnitine to TMAO ScienceDirect Frontiers Gut Microbiota Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target A systematic review of TMAO, microRNAs, and the oral gut microbiomes in atherosclerosis and myocardial infarction: mechanistic insights and translational opportunities Journal of Translational Medicine Springer Nature Link Trimethylamine N Oxide (TMAO) as a Rising Star Metabolite: Implications for Human Health Trimethylamine N Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet Journal of Renal Nutrition

SKU: 9490117302 · From reganhouse.co.nz